Search Results

Ventana Medical Systems, Inc. developed the Ventana CEA Primary Antibody for use on the Ventana ES automated slide staining system. Ventana CEA Primary Antibody (clone TF 3H8-1) is substantially equivalent to a commercially available anti-human cytokeratin (clone CAM 5.2) in that they both stain antigens on cells of epithelial origin.

AI/ML Overview

Here's an analysis of the provided text, focusing on acceptance criteria and the study details:

The provided text, K94034J, is a 510(k) Summary of Safety and Effectiveness for the Ventana CEA Primary Antibody. This document describes a comparative study to demonstrate substantial equivalence to a commercially available anti-human cytokeratin antibody.

Acceptance Criteria and Reported Device Performance

The document doesn't explicitly state quantitative acceptance criteria in a pass/fail format with specific thresholds. Instead, it focuses on demonstrating "substantially equivalent" performance to a predicate device in terms of staining patterns and specificity. The key performance indicators evaluated are:

Acceptance Criteria (Inferred from study goals)	Reported Device Performance (Ventana CEA Primary Antibody)
Staining Pattern Equivalency to Predicate (CAM 5.2) on Epithelial Tissues	Stained the same epithelial cells (normal breast, anexal glandular cells of skin, glandular cells of stomach, prostate, pancreas) as the predicate.
Specificity (No Inappropriate Staining)	No inappropriate staining of tissue observed.
Agreement with Predicate for Epithelial Line Cancers	Stained the same tissues as the predicate 78% of the time for epithelial line cancers.
Absence of Staining for Non-Epithelial/Non-Mesothelial Cancers	Did not stain any non-epithelial or non-mesothelial type cancers (same as predicate).
Appropriate Staining of Cells of Epithelial Origin	Showed appropriate staining of cells of epithelial origin.
No Staining of Cells of Endodermal Origin	Showed no staining of cells of endodermal origin.
Sensitivity for Known Positive Tissues	Consistent staining of 9 of 10 breast malignancies and 10 of 10 colon malignancies. Appropriate staining of normal epithelial tissue.
Negative Control Performance	Negative results observed with negative controls, with one exception attributed to tissue interference (1+ background).
Inter-run Reproducibility	Equivalent staining across 16 different instrument runs using samples of the same tissue.
Intra-run Reproducibility	Equivalent staining for 10 samples of the same tissue within one run.

Study Details

Sample size used for the test set and the data provenance:
- Sample Size:
  - "Paraffin embedded preparations from normal and pathologic samples" were used. The exact number of samples is not specified, but it encompassed various normal tissues (breast, skin, stomach, prostate, pancreas, brain, pituitary, kidney) and pathologic samples (epithelial line cancers, breast malignancies (10 cases), colon malignancies (10 cases), non-epithelial/non-mesothelial cancers).
  - For reproducibility: 16 samples of the same tissue for inter-run; 10 samples of the same tissue for intra-run.
- Data Provenance: "Samples were obtained from excess tissues obtained for reasons other than the present study." This indicates a retrospective collection of samples, likely from a pathology archive. The country of origin is not specified.
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- Number of Experts: One ("a qualified pathologist").
- Qualifications of Experts: Desc

Ask a Question

Ask a specific question about this device

Page 1 of 1